Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Journal of Hepatology|2018Cited by 133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort StudyPaolo Bonfanti, Tiziana Quirino, Laura Valsecchi et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000Cited by 115
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort StudyPaolo Bonfanti, Tiziana Quirino, Laura Valsecchi et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000Cited by 97
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failureElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 92
Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapiesVelia Chiara Di Maio, Francesca Ceccherini‐Silberstein, Valeria Cento et al.|Liver International|2017Cited by 90